NASDAQ:BPTH - Bio-Path Stock Price, Price Target & More

Sign in or create an account to add this stock to your watchlist.
$1.77 +0.02 (+1.14 %)
(As of 06/19/2018 04:00 PM ET)
Previous Close$1.77
Today's Range$1.68 - $1.80
52-Week Range$1.53 - $5.85
Volume25,648 shs
Average Volume26,820 shs
Market Capitalization$20.07 million
P/E RatioN/A
Dividend YieldN/A
Beta2.73
Bio-Path logoBio-Path Holdings, Inc. operates as a clinical and preclinical stage oncology focused RNAi nano particle drug development company in the United States. The company develops products based on DNAbilize, a drug delivery and antisense technology that uses P-ethoxy, which is a deoxyribonucleic acid (DNA) backbone modification intended to protect the DNA from destruction. Its lead drug candidate is prexigebersen, which is in Phase II clinical trials for the treatment of acute myeloid leukemia and chronic myelogenous leukemia; and in preclinical studies for solid tumors, including breast cancer and ovarian cancer. The company is also developing Liposomal Bcl2 for the treatment of lymphoma; and Liposomal Stat3 that is in preclinical stage for the treatment of pancreatic cancer. It has license agreement with The University of Texas relating to the delivery technology platform for antisense nucleic acids, including two single nucleic acid drug products. Bio-Path Holdings, Inc. was founded in 2007 and is based in Bellaire, Texas.

Receive BPTH News and Ratings via Email

Sign-up to receive the latest news and ratings for BPTH and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:BPTH
CUSIPN/A
Phone832-742-1357

Debt

Debt-to-Equity RatioN/A
Current Ratio6.38
Quick Ratio6.38

Price-To-Earnings

Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual Sales$40,000.00
Price / Sales501.80
Cash FlowN/A
Price / CashN/A
Book Value$0.71 per share
Price / Book2.49

Profitability

EPS (Most Recent Fiscal Year)N/A
Net Income$-7,020,000.00
Net MarginsN/A
Return on Equity-109.22%
Return on Assets-98.99%

Miscellaneous

Employees9
Outstanding Shares11,340,000

Bio-Path (NASDAQ:BPTH) Frequently Asked Questions

What is Bio-Path's stock symbol?

Bio-Path trades on the NASDAQ under the ticker symbol "BPTH."

When did Bio-Path's stock split? How did Bio-Path's stock split work?

Bio-Path's stock reverse split before market open on Thursday, February 8th 2018. The 1-10 reverse split was announced on Friday, February 9th 2018. The number of shares owned by shareholders was adjusted after the closing bell on Friday, February 9th 2018. An investor that had 100 shares of Bio-Path stock prior to the reverse split would have 10 shares after the split.

How were Bio-Path's earnings last quarter?

Bio-Path Holdings Inc (NASDAQ:BPTH) issued its earnings results on Wednesday, May, 16th. The company reported ($0.17) earnings per share for the quarter, topping analysts' consensus estimates of ($0.20) by $0.03. View Bio-Path's Earnings History.

When is Bio-Path's next earnings date?

Bio-Path is scheduled to release their next quarterly earnings announcement on Wednesday, August, 8th 2018. View Earnings Estimates for Bio-Path.

What price target have analysts set for BPTH?

1 brokers have issued 12-month price targets for Bio-Path's stock. Their predictions range from $15.00 to $15.00. On average, they expect Bio-Path's share price to reach $15.00 in the next twelve months. View Analyst Ratings for Bio-Path.

Who are some of Bio-Path's key competitors?

Who are Bio-Path's key executives?

Bio-Path's management team includes the folowing people:
  • Mr. Peter H. Nielsen, Co-Founder, Chairman, CEO, Pres, CFO & Treasurer (Age 69)
  • Mr. Douglas P. Morris, Co-Founder, Director of Investor Relations, Sec. & Director (Age 62)
  • Mr. Anthony Price MBA, Director of Fin. and Accounting
  • Dr. Ana Tari Ashizawa, Director of Research
  • Dr. Suzanne Kennedy Ph.D., Director of Corp. Devel.

Has Bio-Path been receiving favorable news coverage?

Media stories about BPTH stock have trended positive recently, according to Accern Sentiment. The research firm identifies negative and positive media coverage by monitoring more than 20 million news and blog sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores closest to one being the most favorable. Bio-Path earned a news impact score of 0.27 on Accern's scale. They also assigned news articles about the company an impact score of 44.75 out of 100, meaning that recent media coverage is somewhat unlikely to have an effect on the company's share price in the immediate future.

Who are Bio-Path's major shareholders?

Bio-Path's stock is owned by many different of retail and institutional investors. Top institutional shareholders include University of Texas Texas AM Investment Managment Co. (3.38%). View Institutional Ownership Trends for Bio-Path.

Which major investors are selling Bio-Path stock?

BPTH stock was sold by a variety of institutional investors in the last quarter, including University of Texas Texas AM Investment Managment Co.. View Insider Buying and Selling for Bio-Path.

How do I buy shares of Bio-Path?

Shares of BPTH can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Bio-Path's stock price today?

One share of BPTH stock can currently be purchased for approximately $1.77.

How big of a company is Bio-Path?

Bio-Path has a market capitalization of $20.07 million and generates $40,000.00 in revenue each year. Bio-Path employs 9 workers across the globe.

How can I contact Bio-Path?

Bio-Path's mailing address is 4710 BELLAIRE BOULEVARD SUITE 210, BELLAIRE TX, 77401. The company can be reached via phone at 832-742-1357 or via email at [email protected]


MarketBeat Community Rating for Bio-Path (BPTH)

Community Ranking:  2.8 out of 5 (star star)
Outperform Votes:  169 (Vote Outperform)
Underperform Votes:  132 (Vote Underperform)
Total Votes:  301
MarketBeat's community ratings are surveys of what our community members think about Bio-Path and other stocks. Vote "Outperform" if you believe BPTH will outperform the S&P 500 over the long term. Vote "Underperform" if you believe BPTH will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 6/19/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.